Cargando…

Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats

This study evaluates safety of FINLAY-FR-02, a vaccine candidate against SARS-CoV-2 based on the recombinant receptor binding domain conjugated to tetanus toxoid, in a preclinical, repeat-dose toxicity and local tolerance study. Sprague Dawley rats were randomly allocated to three experimental group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliva-Hernández, Reynaldo, Fariñas-Medina, Mildrey, Hernández-Salazar, Tamara, Oyarzabal-Vera, Ambar, Infante-Bourzac, Juan F., Rodríguez-Salgueiro, Sandra, Rodríguez-Noda, Laura M., Arranguren-Masorra, Yisabel, Climent-Ruíz, Yanet, Fernández-Castillo, Sonsire, G-Rivera, Daniel, Santana-Mederos, Darielys, Sánchez-Ramírez, Belinda, García-Rivera, Dagmar, Valdés-Barbín, Yury, Vérez-Bencomo, Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961942/ https://www.ncbi.nlm.nih.gov/pubmed/35364223 http://dx.doi.org/10.1016/j.tox.2022.153161

Ejemplares similares

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
por: Puga-Gómez, Rinaldo, et al.
Publicado: (2023)

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
por: Valdes-Balbin, Yury, et al.
Publicado: (2021)

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
por: Ochoa-Azze, Rolando, et al.
Publicado: (2022)

Self-assembled particulate PsaA as vaccine against Streptococcus pneumoniae infection
por: González-Miro, Majela, et al.
Publicado: (2017)

A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
por: Chang-Monteagudo, Arturo, et al.
Publicado: (2021)

James Finlay
Publicado: (1910)

Carlos Finlay
por: Givhan, E. G.
Publicado: (1939)

Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection
por: González-Miró, Majela, et al.
Publicado: (2018)

Weight for Stephen Finlay
por: Evers, Daan
Publicado: (2011)

William A. Finlay
Publicado: (1909)

David White Finlay
Publicado: (1923)

John Finlay Boa
Publicado: (1927)

Finlay Matheson Mackenzie
Publicado: (1919)

Rev. Hunter Finlay
Publicado: (1906)

Glycan Array Evaluation of Synthetic Epitopes between the Capsular Polysaccharides from Streptococcus pneumoniae 19F and 19A
por: Morelli, Laura, et al.
Publicado: (2021)

Dr William Finlay of Trinity
Publicado: (1886)

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
por: Toledo-Romani, María Eugenia, et al.
Publicado: (2022)

Toxicological Assessment of the Cochleate Derived from Neisseria meningitidis Proteoliposome in Sprague Dawley Rats
por: Infante-Bourzac, Juan Francisco, et al.
Publicado: (2012)

Multicomponent polysaccharide–protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates
por: Méndez, Yanira, et al.
Publicado: (2018)

A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
por: Santana-Mederos, Darielys, et al.
Publicado: (2021)

Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)
por: Fraleigh, Nya L., et al.
Publicado: (2016)

Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats
por: Oliva, Reynaldo, et al.
Publicado: (2019)

A Bordetella pertussis proteoliposome induces protection in mice without affecting the immunogenicity of diphtheria and tetanus toxoids in a trivalent formulation
por: Castillo, Sonsire Fernández, et al.
Publicado: (2016)

Evocation to the Dr. Carlos J. Finlay Barres on the centennial of his death
por: Ferreira Moreno, Víctor Guillermo
Publicado: (2016)

Disability, vulnerability and assisted death: commentary on Tuffrey-Wijne, Curfs, Finlay and Hollins
por: Stainton, Tim
Publicado: (2019)

Time to revisit Dr Finlay's casebook? The unique potential of the general practice case report
por: Mallen, Christian D
Publicado: (2009)

Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform
por: Pérez, Oliver, et al.
Publicado: (2013)

FW: An R Package for Finlay–Wilkinson Regression that Incorporates Genomic/Pedigree Information and Covariance Structures Between Environments
por: Lian, Lian, et al.
Publicado: (2015)

Synthetic, Zwitterionic Sp1 Oligosaccharides Adopt a Helical Structure Crucial for Antibody Interaction
por: Zhang, Qingju, et al.
Publicado: (2019)

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
por: Eugenia-Toledo-Romaní, María, et al.
Publicado: (2022)

Fr hjahrstagung
por: Schötzau, H J
Publicado: (1994)

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
por: Pérez-Rodríguez, Sonia, et al.
Publicado: (2022)

FR - Potenciales tratamientos en viruela símica (monkeypox)
por: Rodríguez-Cuadrado, F.J., et al.
Publicado: (2022)

Protective effects of D-005, a lipid extract from Acrocomia crispa fruits, against ischemia/reperfusion-induced acute kidney injury in rats
por: Oyarzábal-Yera, Ambar, et al.
Publicado: (2019)

Decay chains of $^{202}Fr$ and $^{204}Fr$ and $\alpha$ decay branches
por: Bingham, C R, et al.
Publicado: (1995)

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
por: Toledo-Romaní, María Eugenia, et al.
Publicado: (2022)

FR-Vacunación SARS-CoV-2 e inmunoterapia en dermatología
por: Rodríguez-Villa Lario, A., et al.
Publicado: (2022)

Comparative Immune Response after Vaccination with SOBERANA(®) 02 and SOBERANA(®) plus Heterologous Scheme and Natural Infection in Young Children
por: Pérez-Nicado, Rocmira, et al.
Publicado: (2023)

Benefits of D-005, a lipid extract from Acrocomia crispa fruits, in the prevention of acute kidney njury induced by nephrotoxicity in rats
por: Rodríguez-Salgueiro, Sandra, et al.
Publicado: (2021)

A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models
por: Fernández, Sonsire, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qjurh54imgod8qm6djj6h060tm